<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> family consists of several hormones produced by cardiomyocyte, including atrial natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (ANP), brain natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (BNP) and C-type natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (CNP) </plain></SENT>
<SENT sid="1" pm="."><plain>They possess similar gene structures and protective effects of cardiovascular <z:mp ids='MP_0001532'>physiology</z:mp>, such as anti-<z:mpath ids='MPATH_159'>hypertrophy</z:mpath>, anti-<z:mp ids='MP_0003045'>fibrosis</z:mp>, myocardial relaxation and blood pressure regulation </plain></SENT>
<SENT sid="2" pm="."><plain>The corresponding natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> receptor A, B and C mediate multiple effects of natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> to maintain cardiovascular homeostasis </plain></SENT>
<SENT sid="3" pm="."><plain>Specially, natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> receptor-A preferentially binds ANP and BNP, while natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> receptor-B is more selective for C-type natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> receptor-C(NPR-C), binding <z:hpo ids='HP_0000001'>all</z:hpo> kinds of natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi>, clears natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> from the circulation through receptor-mediated internalization and degradation </plain></SENT>
<SENT sid="5" pm="."><plain>BNP levels were reported to be a good predictor of left ventricular dysfunction and decompensated <z:hpo ids='HP_0001635'>heart failure</z:hpo> from a clinical standpoint </plain></SENT>
<SENT sid="6" pm="."><plain>BNP infusion is an effective treatment for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Investigations on natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi>' single nucleotide polymorphisms and biological function suggested that they could be associated with several <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e>, such as <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, <z:hpo ids='HP_0001635'>heart failure</z:hpo> and so on </plain></SENT>
<SENT sid="8" pm="."><plain>Transgenic mice with natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> and their receptors gene deletion display <z:mp ids='MP_0010633'>myocardial hypertrophy</z:mp> and <z:mp ids='MP_0003045'>fibrosis</z:mp>, which are associated with the development of <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Certain stimuli triggering <z:mp ids='MP_0001625'>cardiac hypertrophy</z:mp> and ischemic injuries may be involved in regulating gene expression of natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> and their receptors </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, advances in understanding of natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> family genes and their regulatory mechanisms will lead to greater insight into the pathogenesis of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> and blaze a new trail in clinical treatment </plain></SENT>
</text></document>